Cancerguard® Multi-Cancer Early Detection Test
Use
Cancerguard® test is designed to detect multiple cancer types, including 6 of the most deadly cancers like pancreatic, lung, liver, esophageal, stomach, and ovarian. It is intended to help detect hard-to-find cancers in their early stages when they are more treatable. This test aims to expand screening capabilities by providing earlier cancer detection insights that can significantly impact treatment outcomes. The test detects alterations in circulating tumor DNA and tumor-associated protein levels that are commonly associated with cancer.
Special Instructions
The test is indicated for adults aged 50-84 with no known cancer diagnosis in the last three years. It is not a standalone replacement for existing recommended cancer screenings. Patients with a history of adverse reactions to iodine-based IV contrast or pregnant women should consider carefully before proceeding with the test due to potential follow-up imaging procedures involving IV contrast CT.
Limitations
Cancerguard does not detect all cancer types. While it offers high sensitivity for certain cancers, false negatives and false positives can occur, meaning it might miss cancer signals or indicate cancer where there is none. It is not indicated for breast and prostate cancer screening and was not evaluated for pre-cancerous lesions. Further clinical evaluation, including blood tests and imaging, is needed to confirm a diagnosis following a positive result.
Methodology
NGS
Biomarkers
Result Turnaround Time
14-null days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
One simple blood draw is required for testing.